This past month, OncoSec’s Chief Medical Officer, Dr. Robert Pierce, participated in the 6th Annual Melanoma Research Alliance Scientific Retreat The conference seeks to advance the field of melanoma research, by providing an interactive forum that facilitates data sharing and discussion among key field leaders. This is accomplished through guest participation in a series of collaborative and thought-provoking activities, including panel discussions and notable speaker presentations.
We’ve had a busy year at OncoSec. From our ongoing clinical trials to the formation of our melanoma board, research agreement with Old Dominion University and in between, the last year has moved us deeper into cancer research and engaging with patient communities. As we have only a matter of days left in 2013, we would like to look back at this year in review. Here is a selection of some of our activities this year:
With the severity of many cancer cases, the treatment of cancer is regarded as a very sensitive area. Strict regulations surround the research and delivery of treatment, there are specific protocols used by doctors in diagnosis, and long established doctrine often governs which treatment option is used. Because of these factors, a few cornerstone treatments have surfaced over the years, which still make up the majority of treatments. The two options used most often, aside from surgery for early-stage tumors, are chemotherapy and radiation therapy. Today, we take a look at each therapy method and compare them to immunotherapy.
Clinical trials are a requirement, for any new drug or treatment method attempting to gain approval for public use. The process is meant to show the effectiveness, safety, stability and repeatable nature of the proposed treatment, in order to prove that it works. Clinical trials are a long, intensive process that takes years and millions of dollars to complete. In fact, it is believed that the average drug costs $1.3 billion, to bring it to the point of sale, and as much as $11 billion.
Cancer is a complex public and personal issue. With so many factors increasing and decreasing cancer risk, some of the data can be both confusing and confounding. As well, cancer generally takes a period of years to develop: something that makes people less aware of the dangers. It takes a certain level of knowledge, compassion, and drive to help bridge the gap between the medical treatment of cancer, prevention, and the public. This is where the cancer advocate comes in.